bf/NASDAQ:ADAP_icon.png

NASDAQ:ADAP

Adaptimmune Therapeutics plc

  • Stock

USD

Last Close

0.05

27/10 22:32

Market Cap

293.91M

Beta: 2.24

Volume Today

564.86K

Avg: 683.17K

PE Ratio

−1.68

PFCF: −2.03

OverviewFinancialsAPI

    Description

    Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical tri...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -0.4-0.20.22017-08-032019-02-272021-02-252022-08-042024-05-15

    Revenue (Estimate*)

    100M200M300M400M500M600M2017-08-032019-02-272021-02-252022-08-042024-05-15

    *Estimate based on analyst consensus